- Gross revenues increase by 3.9 percent to 6.3 million Euros

- EBITDA significantly improves to -1.2 million Euros

- Liquidity more than doubles to 1.6 million Euros

curasan AG (ISIN DE0005494538), a leading specialist for medical devices in the field of bone and tissue regeneration, published its 2014 full-results today. Apparently the cost cutting measures of the past months show a generally positive effect on the earnings situation of the company.

During the reporting period gross revenues of curasan AG increased by 3.9 percent to 6.3 million Euros versus 6.0 million Euros in the previous year. Reason for this were particularly clearly risen sales in the dental business of the US subsidiary curasan Inc., overcompensating revenue declines in regions of political instability.

Earnings before interest, taxes, depreciation, and amortization (EBITDA) improved to -1.2 million Euros after -1.6 million Euros in the previous year. The net loss for the year improved slightly disproportionally to -1.7 million Euros after -2.0 million Euros in 2013 due to the financial result. Liquidity doubled compared to the previous year to 1.6 million Euros, as a result of the company's successfully closed capital increase in the fourth quarter.

The new CEO of the company, Michael Schlenk, considers the latest results a good basis for the future success of the company: 'Our cost cutting measures made it possible to almost 1 to 1 pass our revenue increase through to the net result. This is generally a positive signal. To even amplify this effect in the upcoming quarters, we now have to invest our liquidity as intelligently as possible into our marketing and sales efforts.'

After announcing to refocus its sales strategy by the beginning of April 2015, curasan plans to lay the foundation for profitable growth in the future by very selective investments in marketing and sales in the upcoming two years. For the financial year 2015 management and supervisory board of the company thus expect moderately growing revenues. Yet slightly rising costs due to the selective investments will result in a less positive impact of revenue growth on the net result.

On the basis of a conservative results forecast for the fiscal year 2015 the company expects gross revenues of 6.3 to 6.9 million Euros and a net loss of 1.2 to 1.6 million Euros. The company will progressively specify this forecast with every release of upcoming quarterly results.

Upcoming capital markets events of curasan AG:

04/05/2015 DVFA Small Cap Conference Frankfurt CEO/IRO
(including company presentation at 11.25 am)
05/04/2015 DVFA Small Cap Conference Frankfurt CEO/IRO

About curasan AG:
curasan AG specializes in medical products for bone and tissue regeneration in the segment of regenerative medicine. It has set up a ground-breaking product pipeline of synthetic substitution and regeneration materials. Numerous patents and a comprehensive list of scientific documentation have established the clinical success of the products and the highly innovative strength of curasan AG. The list of users include surgically active dentists, implantologists and oral, maxillary and dentofacial surgeons, as well as orthopaedics, traumatologists and spinal column surgeons. The company is listed in the General Standard at the Frankfurt Stock Exchange (ISIN: DE 000 549 453 8).

Contact:
Ingo Middelmenne
Head of Investor Relations
Tel. +49 6027 40900-45
Fax +49 6027 40900-39
ingo.middelmenne@curasan.de


Andrea Weidner
Head of Corporate Communications
Tel. +49 6027 40900-51
Fax +49 6027 40900-39
andrea.weidner@curasan.de
www.curasan.de